Acquired Autoimmune Hemolytic Anemia Market Report 2026

Acquired Autoimmune Hemolytic Anemia Market Overview

• Acquired Autoimmune Hemolytic Anemia market size has reached to $2.14 billion in 2025 • Expected to grow to $3.01 billion in 2030 at a compound annual growth rate (CAGR) of 7.1% • Growth Driver: Increasing Prevalence Of Autoimmune Disorders Driving The Growth Of The Market Due To Immune System Dysregulation • Market Trend: FcRn Blocker Therapies Advancing Treatment For Severe Hemolytic Disease • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Acquired Autoimmune Hemolytic Anemia Market?

Acquired autoimmune hemolytic anemia (AIHA) is a rare disorder that causes anemia when the body's immune system unintentionally targets and kills its own red blood cells it is frequently brought on by infections, autoimmune disorders, malignancies, or specific drugs, and it can appear suddenly or gradually. This happens as a result of the body producing antibodies that attack its own red blood cells, causing hemolysis, or the premature breakdown of those cells. The main diagnostic methods of acquired autoimmune hemolytic anemia are complete blood count, peripheral blood smear, direct Coombs test, and indirect Coombs test. A complete blood count (CBC) is a diagnostic test used to detect anemia by measuring decreased hemoglobin and hematocrit levels, along with an elevated reticulocyte count, indicating increased red blood cell destruction. There are various treatment types, such as corticosteroids, immunosuppressive agents, intravenous immunoglobulin, and rituximab. The disease varies in severity, including mild, moderate, and severe forms. The key end users are hospitals, specialty clinics, and research institutions.

What Is The Acquired Autoimmune Hemolytic Anemia Market Growth Forecast?

The acquired autoimmune hemolytic anemia market size is expected to see strong growth in the next few years. It will grow to $3.01 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to rare disease awareness growth, biologic therapy adoption, advanced diagnostic integration, hematology research funding, personalized treatment protocols. Major trends in the forecast period include increasing use of targeted immunosuppressive therapies, rising adoption of rituximab-based treatment, growth in hospital-based hematology care, improved diagnostic testing adoption, expansion of rare disease treatment programs.

Global Acquired Autoimmune Hemolytic Anemia Market Segmentation

1) By Diagnosis Method: Complete Blood Count, Peripheral Blood Smear, Direct Coombs Test, Indirect Coombs Test 2) By Treatment Type: Corticosteroids, Immunosuppressive Agents, Intravenous Immunoglobulin, Rituximab 3) By Severity: Mild, Moderate, Severe 4) By End User: Hospitals, Specialty Clinics, Research Institutions Subsegments: 1) By Complete Blood Count: Hemoglobin Level, Hematocrit (HCT), Reticulocyte Count, White Blood Cell Count, Platelet Count 2) By Peripheral Blood Smear: Spherocytes, Polychromasia, Schistocytes, Increased Reticulocyte Count 3) By Direct Coombs Test: Immunoglobulin G Coombs Test, Immunoglobulin M Coombs Test, Complement Coombs Test 4) By Indirect Coombs Test: Screening For Alloantibodies, Detection Of Sensitizing Antibodies, Crossmatch Testing

What Is The Driver Of The Acquired Autoimmune Hemolytic Anemia Market?

The increasing prevalence of autoimmune disorders is expected to propel the growth of the acquired autoimmune hemolytic anemia market going forward. Autoimmune disorders are when the body's own healthy cells and tissues are wrongly attacked by the immune system because it believes they are dangerous invaders. The rising prevalence of autoimmune disorders is largely attributed to increased environmental triggers and lifestyle changes that may disrupt immune system regulation. The rising prevalence of autoimmune disorders contributes to a higher incidence of acquired autoimmune hemolytic anemia, as individuals with autoimmune conditions are more likely to develop secondary AIHA due to immune system dysregulation. For instance, in 2023, according to the Gastro-Intestinal Epidemiology Consortium (CanGIEC), a Canada-based national network of researchers and clinicians, the prevalence of inflammatory bowel disease, estimated at 825 cases per 100,000 people. This prevalence is forecasted to rise by 2.44% annually, reaching 1,075 cases per 100,000 people by 2035. Therefore, the increasing prevalence of autoimmune disorders will drive the growth of the acquired autoimmune hemolytic anemia industry.

Key Players In The Global Acquired Autoimmune Hemolytic Anemia Market

Major companies operating in the acquired autoimmune hemolytic anemia market are F. Hoffmann-La Roche Ltd., Alexion Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Sanofi S.A., AbbVie Inc., Novartis AG, Incyte Corporation, BioCryst Pharmaceuticals Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Zenas BioPharma Inc., Immunovant Sciences GmbH, Alpine Immune Sciences Inc., Agios Pharmaceuticals Inc., Johnson & Johnson, Merck KGaA, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, CSL Behring, Grifols S.A.

Global Acquired Autoimmune Hemolytic Anemia Market Trends and Insights

Major companies operating in the acquired autoimmune hemolytic anemia market are focusing on advancements in targeted therapies, such as neonatal Fc receptor (FcRn) blockers, to improve treatment efficacy, enhance maternal-fetal outcomes, and provide more effective interventions for high-risk pregnancies complicated by severe hemolytic disease. An FcRn blocker is a therapeutic antibody designed to inhibit the neonatal Fc receptor, which is responsible for recycling immunoglobulin G (IgG) antibodies in the body, thereby reducing pathogenic antibody levels that cause red blood cell destruction and hemolytic complications in both maternal and fetal populations. For instance, in January 2025, Johnson & Johnson, a US-based pharmaceutical and healthcare company, received U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for nipocalimab for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN). Nipocalimab works by selectively blocking the neonatal Fc receptor (FcRn), reducing maternal IgG antibody levels that cross the placenta and attack fetal red blood cells, thereby preventing severe hemolytic disease, reducing the need for intrauterine transfusions, and improving outcomes for at-risk pregnancies. Nipocalimab specifically targets FcRn-mediated IgG recycling without affecting other immune functions.

What Are Latest Mergers And Acquisitions In The Acquired Autoimmune Hemolytic Anemia Market?

In September 2023, Bristol Myers Squibb, a US-based biopharmaceutical company, acquired the Asian market rights to obexelimab, a bifunctional monoclonal antibody from Zenas BioPharma, for $50 million. With this acquisition, Bristol Myers Squibb aims to expand its immunology portfolio and strengthen its presence in the Asian biopharmaceutical market targeting autoimmune diseases. Zenas BioPharma is a U.S.-based clinical-stage biopharmaceutical company, specializing in developing immunology-based therapies for autoimmune diseases, including acquired autoimmune hemolytic anemia.

Regional Insights

North America was the largest region in the acquired autoimmune hemolytic anemia market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Acquired Autoimmune Hemolytic Anemia Market?

The acquired autoimmune hemolytic anemia market consists of revenues earned by entities by providing services such as diagnosis services, treatment and medication services, clinical trials, and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acquired autoimmune hemolytic anemia market also includes sales of prednisone, and methylprednisolone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Acquired Autoimmune Hemolytic Anemia Market Report 2026?

The acquired autoimmune hemolytic anemia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the acquired autoimmune hemolytic anemia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.